Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 157

1.

Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals.

Tomaras GD, Binley JM, Gray ES, Crooks ET, Osawa K, Moore PL, Tumba N, Tong T, Shen X, Yates NL, Decker J, Wibmer CK, Gao F, Alam SM, Easterbrook P, Abdool Karim S, Kamanga G, Crump JA, Cohen M, Shaw GM, Mascola JR, Haynes BF, Montefiori DC, Morris L.

J Virol. 2011 Nov;85(21):11502-19. doi: 10.1128/JVI.05363-11. Epub 2011 Aug 17.

PMID:
21849452
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals.

Walker LM, Simek MD, Priddy F, Gach JS, Wagner D, Zwick MB, Phogat SK, Poignard P, Burton DR.

PLoS Pathog. 2010 Aug 5;6(8):e1001028. doi: 10.1371/journal.ppat.1001028.

PMID:
20700449
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals.

Li Y, Svehla K, Louder MK, Wycuff D, Phogat S, Tang M, Migueles SA, Wu X, Phogat A, Shaw GM, Connors M, Hoxie J, Mascola JR, Wyatt R.

J Virol. 2009 Jan;83(2):1045-59. doi: 10.1128/JVI.01992-08. Epub 2008 Nov 12.

PMID:
19004942
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection.

Gray ES, Madiga MC, Hermanus T, Moore PL, Wibmer CK, Tumba NL, Werner L, Mlisana K, Sibeko S, Williamson C, Abdool Karim SS, Morris L; CAPRISA002 Study Team.

J Virol. 2011 May;85(10):4828-40. doi: 10.1128/JVI.00198-11. Epub 2011 Mar 9.

PMID:
21389135
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial.

Gottardo R, Bailer RT, Korber BT, Gnanakaran S, Phillips J, Shen X, Tomaras GD, Turk E, Imholte G, Eckler L, Wenschuh H, Zerweck J, Greene K, Gao H, Berman PW, Francis D, Sinangil F, Lee C, Nitayaphan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Tartaglia J, Robb ML, Michael NL, Kim JH, Zolla-Pazner S, Haynes BF, Mascola JR, Self S, Gilbert P, Montefiori DC.

PLoS One. 2013 Sep 26;8(9):e75665. doi: 10.1371/journal.pone.0075665. eCollection 2013.

PMID:
24086607
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination.

Davis KL, Gray ES, Moore PL, Decker JM, Salomon A, Montefiori DC, Graham BS, Keefer MC, Pinter A, Morris L, Hahn BH, Shaw GM.

Virology. 2009 May 10;387(2):414-26. doi: 10.1016/j.virol.2009.02.022. Epub 2009 Mar 18.

PMID:
19298995
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjects.

Sather DN, Stamatatos L.

Vaccine. 2010 May 26;28 Suppl 2:B8-12. doi: 10.1016/j.vaccine.2009.07.085.

PMID:
20510750
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Production and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors.

Andrabi R, Kumar R, Bala M, Nair A, Biswas A, Wig N, Kumar P, Pal R, Sinha S, Luthra K.

Virol J. 2012 Sep 12;9:196. doi: 10.1186/1743-422X-9-196.

PMID:
22971578
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

epitopes immediately below the base of the V3 loop of gp120 as targets for the initial autologous neutralizing antibody response in two HIV-1 subtype B-infected individuals.

Tang H, Robinson JE, Gnanakaran S, Li M, Rosenberg ES, Perez LG, Haynes BF, Liao HX, Labranche CC, Korber BT, Montefiori DC.

J Virol. 2011 Sep;85(18):9286-99. doi: 10.1128/JVI.02286-10. Epub 2011 Jul 6.

PMID:
21734041
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.

Binley JM, Lybarger EA, Crooks ET, Seaman MS, Gray E, Davis KL, Decker JM, Wycuff D, Harris L, Hawkins N, Wood B, Nathe C, Richman D, Tomaras GD, Bibollet-Ruche F, Robinson JE, Morris L, Shaw GM, Montefiori DC, Mascola JR.

J Virol. 2008 Dec;82(23):11651-68. doi: 10.1128/JVI.01762-08. Epub 2008 Sep 24.

PMID:
18815292
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.

Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, Hammond PW; Protocol G Principal Investigators, Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR.

Science. 2009 Oct 9;326(5950):285-9. doi: 10.1126/science.1178746. Epub 2009 Sep 3.

PMID:
19729618
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors.

Dhillon AK, Donners H, Pantophlet R, Johnson WE, Decker JM, Shaw GM, Lee FH, Richman DD, Doms RW, Vanham G, Burton DR.

J Virol. 2007 Jun;81(12):6548-62. Epub 2007 Apr 4.

PMID:
17409160
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals.

Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, Pietzsch J, Ott RG, Anthony RM, Zebroski H, Hurley A, Phogat A, Chakrabarti B, Li Y, Connors M, Pereyra F, Walker BD, Wardemann H, Ho D, Wyatt RT, Mascola JR, Ravetch JV, Nussenzweig MC.

Nature. 2009 Apr 2;458(7238):636-40. doi: 10.1038/nature07930. Epub 2009 Mar 15.

PMID:
19287373
[PubMed - indexed for MEDLINE]
14.

Epitope specificity of cross-clade neutralizing sera from Chinese HIV-1-positive individuals.

Song H, Chu Y, Zhang H, Wang X, Zhang T, Qiu M, Wu H, Wu Z.

Scand J Immunol. 2013 Oct;78(4):357-70. doi: 10.1111/sji.12091.

PMID:
23808939
[PubMed - indexed for MEDLINE]
15.

Multiepitope vaccines intensively increased levels of antibodies recognizing three neutralizing epitopes on human immunodeficiency virus-1 envelope protein.

Lu Y, Xiao Y, Ding J, Dierich MP, Chen YH.

Scand J Immunol. 2000 May;51(5):497-501.

PMID:
10792842
[PubMed - indexed for MEDLINE]
16.

Passively transmitted gp41 antibodies in babies born from HIV-1 subtype C-seropositive women: correlation between fine specificity and protection.

Diomede L, Nyoka S, Pastori C, Scotti L, Zambon A, Sherman G, Gray CM, Sarzotti-Kelsoe M, Lopalco L.

J Virol. 2012 Apr;86(8):4129-38. doi: 10.1128/JVI.06359-11. Epub 2012 Feb 1.

PMID:
22301151
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals.

Corti D, Langedijk JP, Hinz A, Seaman MS, Vanzetta F, Fernandez-Rodriguez BM, Silacci C, Pinna D, Jarrossay D, Balla-Jhagjhoorsingh S, Willems B, Zekveld MJ, Dreja H, O'Sullivan E, Pade C, Orkin C, Jeffs SA, Montefiori DC, Davis D, Weissenhorn W, McKnight A, Heeney JL, Sallusto F, Sattentau QJ, Weiss RA, Lanzavecchia A.

PLoS One. 2010 Jan 20;5(1):e8805. doi: 10.1371/journal.pone.0008805.

PMID:
20098712
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies.

Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C, Stiegler G, Kunert R, Zolla-Pazner S, Katinger H, Petropoulos CJ, Burton DR.

J Virol. 2004 Dec;78(23):13232-52.

PMID:
15542675
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Neutralization of tier-2 viruses and epitope profiling of plasma antibodies from human immunodeficiency virus type 1 infected donors from India.

Andrabi R, Bala M, Kumar R, Wig N, Hazarika A, Luthra K.

PLoS One. 2012;7(8):e43704. doi: 10.1371/journal.pone.0043704. Epub 2012 Aug 31.

PMID:
22952740
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth.

Shen X, Parks RJ, Montefiori DC, Kirchherr JL, Keele BF, Decker JM, Blattner WA, Gao F, Weinhold KJ, Hicks CB, Greenberg ML, Hahn BH, Shaw GM, Haynes BF, Tomaras GD.

J Virol. 2009 Apr;83(8):3617-25. doi: 10.1128/JVI.02631-08. Epub 2009 Feb 4.

PMID:
19193787
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk